Table 2.
The results of meta analysis of included studies.
| Outcome | Number of study | Sample Size(T/C) | Measures | Effect estimate (95 %CI) | Heterogeneity | P | Included studies[ref] |
|---|---|---|---|---|---|---|---|
| Primary outcomes | |||||||
| Length of hospital stay | 1 | 6/6 | MD (—) | −7.95 [-14.66, -1.24] | — | 0.02 | Li29 |
| Rate of 2019-nCov RT-PCR turned to negativity | 1 | 142/142 | RR (—) | 1.08 [0.94, 1.24] | — | 0.28 | Hu28 |
| Clinical symptom score | 2 | 125/125 | MD (Random) | −0.84 [-2.15, 0.47] | I2 = 92% | 0.21 | Duan,25 Qiu,30 |
| Arterial oxygen partial pressure /Fraction of inspired oxygen | 0 | — | — | — | — | — | — |
| Duration of mechanical ventilation | 0 | — | — | — | — | — | — |
| Secondary outcomes | |||||||
| Defervescence time | 2 | 125/125 | MD (Random) | −1.20 [-2.03, -0.38] | I2 = 77% | 0.004 | Qiu,30 Xiao,32 |
| Defervescence rate | 3 | 137/95 | RR (Random) | 1.18 [0.88, 1.60] | I2 = 69% | 0.27 | Ding,24 Duan,25Sun,31 |
| Cough resolution time | 2 | 125/125 | MD (Random) | −1.57 [-4.17, 1.03] | I2 = 94% | 0.24 | Qiu,30 Xiao,32 |
| Cough resolution rate | 3 | 157/107 | RR (Random) | 1.37 [1.15, 1.64] | I2 = 0% | 0.0004 | Ding,24] Duan,25 Sun,31 |
| Fatigue resolution time | 1 | 100/100 | MD (—) | −0.33 [-0.78, 0.12] | — | 0.15 | Xiao32 |
| Fatigue resolution rate | 2 | 96/51 | RR (Random) | 1.37 [1.02, 1.83] | I2 = 11% | 0.04 | Duan,,25Sun,31 |
| Tachypnea resolution rate | 1 | 18/17 | RR (—) | 2.20 [1.11, 4.39] | — | 0.02 | Ding,24 |
| Diarrhea resolution rate | 2 | 17/13 | RR (Random) | 0.32 [0.01, 15.49] | I2 = 87% | 0.56 | Ding,24 Duan,25 |
| Body pain resolution rate | 1 | 18/12 | RR (—) | 1.17 [0.73, 1.87] | — | 0.52 | Duan,25 |
| Adverse events | 8 | 597/555 | RD (Random) | 0.03 [-0.02, 0.08] | I2 = 83% | 0.31 | Ding,24 Duan,25 Fu_a,,26Fu_b,27 Hu,28Li,29Xiao,32Yu34 |
T, Treatment group/Experimental group; C, control group; MD, mean difference; RR, risk ratio;